Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Research Article

Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies

Author(s): Clodoveo Ferri*, Vincenzo Raimondo, Laura Gragnani, Dilia Giuggioli, Lorenzo Dagna, Antonio Tavoni, Francesco Ursini, Massimo L'Andolina, Francesco Caso, Piero Ruscitti, Maurizio Caminiti, Rosario Foti, Valeria Riccieri, Serena Guiducci, Roberta Pellegrini, Elisabetta Zanatta, Giuseppe Varcasia, Domenico Olivo, Pietro Gigliotti, Giovanna Cuomo, Giuseppe Murdaca, Riccardo Cecchetti, Rossella De Angelis, Nicoletta Romeo, Francesca Ingegnoli, Franco Cozzi, Veronica Codullo, Ilaria Cavazzana, Michele Colaci, Giuseppina Abignano, Maria De Santis, Ennio Lubrano, Enrico Fusaro, Amelia Spinella, Federica Lumetti, Giacomo De Luca, Silvia Bellando-Randone, Elisa Visalli, Ylenia Dal Bosco, Giorgio Amato, Daiana Giannini, Silvia Bilia, Francesco Masini, Greta Pellegrino, Erika Pigatto, Elena Generali, Giuseppa Pagano Mariano, Giorgio Pettiti, Giovanni Zanframundo, Raffaele Brittelli, Vincenzo Aiello, Rodolfo Caminiti, Daniela Scorpiniti, Tommaso Ferrari, Corrado Campochiaro, Veronica Brusi, Micaela Fredi, Liala Moschetti, Fabio Cacciapaglia, Sabrina Rosaria Paparo, Francesca Ragusa, Valeria Mazzi, Giusy Elia, Silvia Martina Ferrari, Ilenia Di Cola, Marta Vadacca, Sebastiano Lorusso, Monica Monti, Serena Lorini, Maria Letizia Aprile, Marco Tasso, Mario Miccoli, Silvia Bosello, Salvatore D'Angelo, Andrea Doria, Franco Franceschini, Riccardo Meliconi, Marco Matucci-Cerinic, Florenzo Iannone, Roberto Giacomelli, Carlo Salvarani, Anna Linda Zignego, Poupak Fallahi and Alessandro Antonelli*

Volume 28, Issue 24, 2022

Published on: 18 July, 2022

Page: [2022 - 2028] Pages: 7

DOI: 10.2174/1381612828666220614151732

Price: $65

conference banner
Abstract

Objective: Autoimmune systemic diseases (ASD) represent a predisposing condition to COVID-19. Our prospective, observational multicenter telephone survey study aimed to investigate the prevalence, prognostic factors, and outcomes of COVID-19 in Italian ASD patients.

Methods: The study included 3,918 ASD pts (815 M, 3103 F; mean age 59±12SD years) consecutively recruited between March 2020 and May 2021 at the 36 referral centers of COVID-19 and ASD Italian Study Group. The possible development of COVID-19 was recorded by means of a telephone survey using a standardized symptom assessment questionnaire.

Results: ASD patients showed a significantly higher prevalence of COVID-19 (8.37% vs. 6.49%; p<0.0001) but a death rate statistically comparable to the Italian general population (3.65% vs. 2.95%). Among the 328 ASD patients developing COVID-19, 17% needed hospitalization, while mild-moderate manifestations were observed in 83% of cases. Moreover, 12/57 hospitalized patients died due to severe interstitial pneumonia and/or cardiovascular events; systemic sclerosis (SSc) patients showed a significantly higher COVID-19-related death rate compared to the general population (6.29% vs. 2.95%; p=0.018). Major adverse prognostic factors to develop COVID-19 were: older age, male gender, SSc, pre-existing ASD-related interstitial lung involvement, and long-term steroid treatment. Of note, patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) showed a significantly lower prevalence of COVID-19 compared to those without (3.58% vs. 46.99%; p=0.000), as well as the SSc patients treated with low dose aspirin (with 5.57% vs. without 27.84%; p=0.000).

Conclusion: During the first three pandemic waves, ASD patients showed a death rate comparable to the general population despite the significantly higher prevalence of COVID-19. A significantly increased COVID-19- related mortality was recorded in only SSc patients’ subgroup, possibly favored by preexisting lung fibrosis. Moreover, ongoing long-term treatment with csDMARDs in ASD might usefully contribute to the generally positive outcomes of this frail patients’ population.

Keywords: COVID-19, autoimmune systemic diseases, systemic sclerosis, vasculitis, interstitial lung involvement, steroids, DMARD, aspirin.

[1]
Costa L, Tasso M, Scotti N, et al. Telerheumatology in COVID-19 era: A study from a psoriatic arthritis cohort. Ann Rheum Dis 2021; 80: e46.
[2]
Fagni F, Simon D, Tascilar K, et al. COVID-19 and immune-mediated inflammatory diseases: Effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol 2021; 3(10): e724-36.
[http://dx.doi.org/10.1016/S2665-9913(21)00247-2] [PMID: 34485930]
[3]
Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 2020; 79(10): 1382-3.
[http://dx.doi.org/10.1136/annrheumdis-2020-217717] [PMID: 32398281]
[4]
Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and rheumatic autoimmune systemic diseases: Report of a large Italian patients series. Clin Rheumatol 2020; 39(11): 3195-204.
[http://dx.doi.org/10.1007/s10067-020-05334-7] [PMID: 32852623]
[5]
Ferri C, Giuggioli D, Raimondo V, Fallahi P, Antonelli A. Group C-AIS. COVID-19 in Italian patients with rheumatic autoimmune systemic diseases. Ann Rheum Dis 2020; annrheumdis 2020; 219113.
[6]
Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79(5): 667-8.
[http://dx.doi.org/10.1136/annrheumdis-2020-217424] [PMID: 32241793]
[7]
Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis 2021; 80(2): e18.
[http://dx.doi.org/10.1136/annrheumdis-2020-217615] [PMID: 32321723]
[8]
Conticini E, Bargagli E, Bardelli M, et al. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Ann Rheum Dis 2021; 80(2): e14.
[http://dx.doi.org/10.1136/annrheumdis-2020-217681] [PMID: 32414804]
[9]
Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases - case series from new york. N Engl J Med 2020; 383(1): 85-8.
[http://dx.doi.org/10.1056/NEJMc2009567] [PMID: 32348641]
[10]
Jones VG, Mills M, Suarez D, et al. COVID-19 and kawasaki disease: Novel virus and novel case. Hosp Pediatr 2020; 10(6): 537-40.
[http://dx.doi.org/10.1542/hpeds.2020-0123] [PMID: 32265235]
[11]
Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet 2020; 395(10239): 1771-8.
[http://dx.doi.org/10.1016/S0140-6736(20)31103-X] [PMID: 32410760]
[12]
Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond) 2020; 20(2): 124-7.
[http://dx.doi.org/10.7861/clinmed.2019-coron] [PMID: 32139372]
[13]
Antonelli A, Fallahi P, Elia G, et al. Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases. Lancet Rheumatol 2021; 3(10): e675-6.
[http://dx.doi.org/10.1016/S2665-9913(21)00243-5] [PMID: 34316725]
[14]
Manica M, Guzzetta G, Riccardo F, et al. Impact of tiered restrictions on human activities and the epidemiology of the second wave of COVID-19 in Italy. Nat Commun 2021; 12(1): 4570.
[http://dx.doi.org/10.1038/s41467-021-24832-z] [PMID: 34315899]
[15]
Bijlsma JWJ, Hachulla E, Eds. EULAR Textbook on Rheumatic Diseases. 3rd ed. United Kingdom: BMJ Publishing Group 2018.
[16]
Riccardo F, Bella A, Del Manso M, et al. Task force COVID-19 del dipartimento malattie infettive eservizio di informatica, istituto superiore di sanità. Epidemia COVID-19.Aggiornamento nazionale: 4 agosto 2021 In: (ISS) ISdS. Rome. 2020; pp. 1-22.
[17]
Mikuls TR, Johnson SR, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: Version 1. Arthritis Rheumatol 2020; 72(8): 1241-51.
[http://dx.doi.org/10.1002/art.41301] [PMID: 32349183]
[18]
Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and systemic sclerosis: Clinicopathological implications from Italian nationwide survey study. Lancet Rheumatol 2021; 3(3): e166-8.
[http://dx.doi.org/10.1016/S2665-9913(21)00007-2] [PMID: 33521657]
[19]
Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and rheumatic autoimmune systemic diseases: Role of pre-existing lung involvement and ongoing treatments. Curr Pharm Des 2021; 27(41): 4245-52.
[http://dx.doi.org/10.2174/1381612827666210903103935] [PMID: 34477509]
[20]
Shin YH, Shin JI, Moon SY, et al. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol 2021; 3(10): e698-706.
[http://dx.doi.org/10.1016/S2665-9913(21)00151-X] [PMID: 34179832]
[21]
Rutter M, Lanyon PC, Grainge MJ, et al. COVID-19 infection, admission and death amongst people with rare autoimmune rheumatic disease in england. Results from the RECORDER KLject. Rheumatology 2021; (Oxford): keab794.
[22]
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584(7821): 430-6.
[http://dx.doi.org/10.1038/s41586-020-2521-4] [PMID: 32640463]
[23]
Freites Nuñez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79(11): 1393-9.
[http://dx.doi.org/10.1136/annrheumdis-2020-217984] [PMID: 32769150]
[24]
FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020; 80: 527-38.
[25]
Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 2020; 79(7): 859-66.
[http://dx.doi.org/10.1136/annrheumdis-2020-217871] [PMID: 32471903]
[26]
Marques CDL, Kakehasi AM, Pinheiro MM, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: First results of ReumaCoV Brasil registry. RMD Open 2021; 7(1): e001461.
[http://dx.doi.org/10.1136/rmdopen-2020-001461] [PMID: 33510041]
[27]
Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. Lancet Rheumatol 2021; 3(6): e419-26.
[http://dx.doi.org/10.1016/S2665-9913(21)00059-X] [PMID: 33786454]
[28]
D’Arminio Monforte A, Tavelli A, Bai F, et al. Declining mortality rate of hospitalised patients in the second wave of the covid-19 epidemics in italy: Risk factors and the age-specific patterns. Life (Basel) 2021; 11(9): 979.
[http://dx.doi.org/10.3390/life11090979] [PMID: 34575128]
[29]
Ceribelli A, Motta F, De Santis M, et al. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun 2020; 109: 102442.
[http://dx.doi.org/10.1016/j.jaut.2020.102442] [PMID: 32253068]
[30]
Atzeni F, Masala IF, Rodríguez-Carrio J, et al. The rheumatology drugs for COVID-19 Management: Which and when? J Clin Med 2021; 10(4): 783.
[http://dx.doi.org/10.3390/jcm10040783] [PMID: 33669218]
[31]
Hertanto DM, Wiratama BS, Sutanto H, Wungu CDK. Immunomodulation as a potent COVID-19 pharmacotherapy: Past, present and future. J Inflamm Res 2021; 14: 3419-28.
[http://dx.doi.org/10.2147/JIR.S322831] [PMID: 34321903]
[33]
Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study. Ann Rheum Dis 2021; 80(10): 1330-8.
[http://dx.doi.org/10.1136/annrheumdis-2021-220647] [PMID: 34127481]
[34]
Ferri C, Ursini F, Gragnani L, et al. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups. J Autoimmun 2021; 125: 102744.
[http://dx.doi.org/10.1016/j.jaut.2021.102744] [PMID: 34781162]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy